Tonix Pharmaceuticals Added to Russell 3000 and 2000 Indexes, Signaling Growth and Potential FDA Approval

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has been added to the Russell 3000® and Russell 2000® Indexes, a move that underscores the company's market capitalization growth and its progress toward the potential FDA approval of TNX-102 SL for fibromyalgia. This inclusion, effective June 30, 2025, is a testament to Tonix's development trajectory and its efforts to address unmet medical needs in pain management and public health challenges.

The Russell indexes are pivotal benchmarks in the investment world, with approximately $10.6 trillion in assets tied to their performance. Tonix's CEO, Seth Lederman, emphasized that this milestone enhances the company's visibility as it advances toward the commercialization of TNX-102 SL. The product candidate, which has completed two statistically significant phase 3 studies for fibromyalgia management, has been granted Fast Track designation by the FDA, indicating its potential to address a significant unmet medical need.

Beyond fibromyalgia, Tonix is exploring the application of TNX-102 SL in treating acute stress reaction and has secured a contract with the U.S. Department of Defense for the development of TNX-4200, aimed at improving medical readiness against biological threats. The company's comprehensive portfolio also includes treatments for CNS disorders, immunology, rare diseases, and infectious diseases, showcasing its commitment to innovation in biopharmaceuticals.

For more details on Tonix Pharmaceuticals' recent achievements and future directions, visit https://ibn.fm/KCfwJ.